![]() | ![]() |
Formats:
|
||||||||||
Upconverting Luminescent Nanomaterials: Application to In Vivo Bioimaging a Center for Molecular Imaging Research and Center for Systems Biology, Harvard Medical School / Massachusetts General Hospital Room 6229, 149 13th St, Charlestown, MA, 02129 USA. b Department of Radiology, Nuclear Medicine, Harvard Medical School / Massachusetts General Hospital Boston, MA, USA. Fax: +1 617−726−5788; Tel: +1 617−726−5708 E-mail: Scott_Hilderbrand/at/hms.harvard.edu The publisher's final edited version of this article is available at Chem Commun (Camb).Abstract In this report, the development of multi-channel Anti-Stokes luminescent Y2O3 nanoparticles for application to in vivo upconversion imaging is detailed. Luminescent upconverting materials have been known for over 50 years. Only recently has interest focused on preparing these compounds on a nanoscale for applications in biotechnology.1 Current optical imaging and assay technologies primarily are based on the use of organic fluorophores or semiconducting quantum dots.2 Materials, such as yttrium oxide (Y2O3) doped with rare earth elements offer an emerging alternative for use in optical imaging. Erbium and ytterbium containing Y2O3 particles absorb near infrared light at 980 nm and can emit higher energy, shorter wavelength photons in an Anti-Stokes emission process.3 For bioimaging applications Anti-Stokes luminescence offers key advantages over traditional downconversion emission observed with organic fluorphores and quantum dots. One issue concerning the use of small molecule fluophores is a lack of photostability under prolonged excitation. Unlike organic dyes, upconverting Y2O3 nanomaterials show excellent photostability and low toxicity.4 Quantum dots also have excellent photostability, but there are potential cytotoxicity issues associated with their use in vivo due to their inclusion of highly toxic metals such as cadmium,5 which is released in the presence of the biological oxidant hypochlorous acid.6 Tissue autofluorescence is another concern with the use of small molecule fluorophores for in vivo imaging. There are few if any intrinsic biological materials that display upconversion emission, therefore, upconversion emission processes may significantly limit this source of interference. For use of upconverting nanomaterials as in vivo imaging agents, several criteria must be met. These include near infrared excitation and emission, water solubility, biocompatibility, and means for attachment of additional optical reporters or targeting molecules. In the past few years, there have been reports of upconverting nanoparticle preparations that meet some of these criteria.7 In vivo optical imaging focuses on the use of luminescent reporters that have excitation and emission in the NIR (~600−1000 nm) where light absorption and scattering from biological tissues is minimized.8 Excitation and emission in this wavelength range can be achieved by use of Y2O3 nanoparticles co-doped with erbium and ytterbium.3 These particles may be excited using simple 980 nm diode lasers and show upconversion emission in the green or far-red/NIR depending on the concentrations of the dopants. Here we detail the preparation of surface modified upconverting Y2O3 nanoparticles containing erbium and ytterbium, which are suitable for conjugation to additional optical reporters or targeting groups. Importantly these materials can be excited with non-harmful doses of light and have luminescence emission centered at 660 nm. The utility of these particles for in vivo blood pool imaging is demonstrated by visualization of the vasculature in a mouse model after intravenous injection of the nanoparticles. Although there are some reports of water dispersable nanoparticles,2a, 2c, 7b, 9 most methods to produce these materials yield either uncoated or hydrophobic particles that aggregate strongly or do not suspend in water. As a general approach to preparation of water-soluble upconverting nanoparticles, we developed a simple procedure for the surface coating of unmodified Y2O3 particles based on carboxylic acid coordination to the particles (Scheme 1
The PEG and NIR fluorophore modified nanoparticles are easily dispersed in water. The measured mean hydrodynamic diameter of the particles is 101 nm as determined by Dynamic Light Scattering (DLS) experiments (Fig. 1a
The upconversion emission centered at 660 nm is readily detected upon excitation of a dilute (500 μg/mL) aqueous solution of the nanoparticles with a 980 nm diode laser at an excitation power density of 500 mW/cm2 (Fig. 1c The application of the dual channel upconverting nanoparticles to in vivo vascular imaging was studied. Small animal imaging was performed following tail vein injection of the nanoparticles intonudemice. For the imaging experiments a custom built microscope system containing a 980 nm diode laser, for upconversion excitation, and a 737 nm laser, for excitation of the NIR fluorophore, was used. Following probe injection, blood vessels in the mouse ear were imaged. The probe is clearly visible through a 750 nm short-pass filter using the 980 nm diode laser for excitation at a measured laser power density of 550 mW/cm2 (Fig. 2
In conclusion, the ability of lanthanide-based nanomaterials to undergo upconversion luminescence emission has been known for many years, however, only recently have efforts been put forth to develop these materials into biocompatible agents. In this report, an efficient route for preparation of upconverting Y2O3 nanoparticles suitable for in vivo imaging is demonstrated. The aqueous dispersible nanoparticles are coated with PEG polymers and NIR emitting carbocyanine fluorophores. Little or no quenching of the attached carbocyanine fluorophores is observed even with a dye loading of over 1000 dyes per nanoparticle. Preliminary data with these materials show they have low cytotoxicity. The upconversion emission signal from the particles is readily visible in vivo with excitation using a clinically relevant laser power density at 980 nm. Practical utility for imaging the vasculature in live mice is demonstrated with the nanoparticles. These initial studies indicate that this functionalized Y2O3-based upconverting nanomaterial is a promising platform for in vivo optical-based diagnostic imaging. suppl Click here to view.(2.6M, doc) Acknowledgments This research was supported in part by NIH grants U01-HL080731, R01-EB001872, U54-CA119349, P50-CA86355, R24-CA92782, and T32-EB002102. Footnotes †Electronic Supplementary Information (ESI) available: Detailed synthetic and imaging procedures including full characterization data for all compounds and materials. References 1. a. Corstjens PLAM, Li S, Zuiderwijk M, Dardos K, Abrahms WR, Niedbla RS, Tanke HJ. IEEE Proc. Nanobiotechnol. 2005;152:64. [PubMed] b. Kunigas K, Pakkila H, Ukonaho T, Rantanen T, Lovgren T, Soukka T. Clinical Chem. 2007;53:145. [PubMed] c. Chen Z, Chen H, Hu H, Yu M, Li F, Zhang Q, Zhou Z, Yi T, Huang C. J. Am. Chem. Soc. 2008;130:3023. [PubMed] d. Rantanen T, Jarvenpaa M-L, Vuojola J, Kuningas K, Soukka T. Angew. Chem. Int. Ed. 2008;47:3811. [PubMed] 2. a. Chatterjee DK, Rufaihah AJ, Zhang Y. Biomaterials. 2008;29:937. [PubMed] b. Lim SF, Riehn R, Ryu WS, Khanarian N, Tung C-K, Tank D, Austin RH. Nano Lett. 2006;6:169. [PubMed] c. Nyk M, Kumar R, Ohulchanskyy TY, Bergey EJ, Prasad PN. Nano Lett. 2008;8:3834. [PubMed] 3. Vetrone F, Boyer JC, Capobianco JA, Speghini A, Bettinelli M. J. Phys. Chem. C. 2003;107:1107. 4. a. Schubert D, Dargusch R, Raitano J, Chan S-W. Biochem. Biophys. Res. Commun. 2006;342:86. [PubMed] b. Palmer RJ, Butenhoff JL, Stevens JB. Environ. Res. 1987;43:142. [PubMed] 5. Derfus AM, Chan WCW, Bhatia SN. Nano Lett. 2004;4:11. 6. Mancini MC, Kairdolf BA, Smith AM, Nie S. J. Am. Chem. Soc. 2008;130:10836. [PubMed] 7. a. Kamimura M, Miyamoto D, Saito Y, Soga K, Nagasaki Y. Langmuir. 2008;24:8864. [PubMed] b. Schäfer H, Ptacek P, Kömpe K, Haase M. Chem. Mater. 2007;19:1396. [PubMed] 8. Weissleder R, Ntziachristos V. Nat. Med. 2003;9:123. [PubMed] 9. Traina CA, Schwartz J. Langmuir. 2007;23:9158. [PubMed] 10. Pedersen H, Söderlind F, Petoral RMJ, Uvdal K, Käll P-O, Ojamäe L. Surf. Sci. 2005;592:124. 11. Söderlind F, Pedersen H, Petoral RMJ, Käll P-O, Uvdal K. J. Colloid Interface Sci. 2005;288:140. [PubMed] 12. Bentzen EL, Tomlinson ID, Mason J, Gresch P, Warnement MR, Sanders-Bush E, Blakely R, Rosenthal SJ. Bioconjugate Chem. 2005;16:1488. 13. Ballou B, Lagerholm C, Ernst LA, Bruchez MP, Waggoner AS. Bioconjugate Chem. 2004;15:79. 14. Jalil RA, Zhang Y. Biomaterials. 2008;29:4122. [PubMed] 15. a. Josephson L, Kircher MF, Mahmood U, Tang Y, Weissleder R. Bioconjugate Chem. 2002;13:554. b. Turro NJ, Lakshminarasimhan PH, Jockusch S, O'Brien SP, Grancharov SG, Redl FX. Nano Lett. 2002;2:325. 16. Nerambourg N, Werts MHV, Charlot M, Blanchard-Desce M. Langmuir. 2007;23:5563. [PubMed] 17. American National Standard for Safe Use of Lasers ANSI Z136.1−2000. American National Standard Institute; Orlando, FL: 2000. |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||
Clin Chem. 2007 Jan; 53(1):145-6.
[Clin Chem. 2007]Biomaterials. 2008 Mar; 29(7):937-43.
[Biomaterials. 2008]Biochem Biophys Res Commun. 2006 Mar 31; 342(1):86-91.
[Biochem Biophys Res Commun. 2006]J Am Chem Soc. 2008 Aug 20; 130(33):10836-7.
[J Am Chem Soc. 2008]Langmuir. 2008 Aug 19; 24(16):8864-70.
[Langmuir. 2008]Nat Med. 2003 Jan; 9(1):123-8.
[Nat Med. 2003]Biomaterials. 2008 Mar; 29(7):937-43.
[Biomaterials. 2008]Langmuir. 2008 Aug 19; 24(16):8864-70.
[Langmuir. 2008]Langmuir. 2007 Aug 28; 23(18):9158-61.
[Langmuir. 2007]J Colloid Interface Sci. 2005 Aug 1; 288(1):140-8.
[J Colloid Interface Sci. 2005]Biochem Biophys Res Commun. 2006 Mar 31; 342(1):86-91.
[Biochem Biophys Res Commun. 2006]Biomaterials. 2008 Mar; 29(7):937-43.
[Biomaterials. 2008]Biomaterials. 2008 Oct; 29(30):4122-8.
[Biomaterials. 2008]Langmuir. 2007 May 8; 23(10):5563-70.
[Langmuir. 2007]